Literature DB >> 18285562

Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study.

Hiroshi Watanabe1, Naohito Tanabe, Toru Watanabe, Dawood Darbar, Dan M Roden, Shigeru Sasaki, Yoshifusa Aizawa.   

Abstract

BACKGROUND: The metabolic syndrome consists of a cluster of atherosclerotic risk factors, many of which also have been implicated in the genesis of atrial fibrillation (AF). However, the precise role of the metabolic syndrome in the development of AF is unknown. METHODS AND
RESULTS: This prospective, community-based, observational cohort study was based on an annual health check-up program in Japan. We studied 28 449 participants without baseline AF. We used 2 different criteria for the metabolic syndrome--the guidelines of the National Cholesterol Education Program Third Adult Treatment Panel (NCEP-ATP III) and those of the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI)--to study the risk of development of new-onset AF. The metabolic syndrome was present in 3716 subjects (13%) and 4544 subjects (16%) using the NCEP-ATP III and AHA/NHLBI definitions, respectively. During a mean follow-up of 4.5 years, AF developed in 265 subjects (105 women). Among the metabolic syndrome components, obesity (age- and sex-adjusted hazard ratio [HR], 1.64), elevated blood pressure (HR, 1.69), low high-density lipoprotein cholesterol (HR, 1.52), and impaired fasting glucose [corrected] (HR, 1.44 [NCEP-ATP III] and 1.35 [AHA/NHLBI]) showed an increased risk for AF. The association between the metabolic syndrome and AF remained significant in subjects without treated hypertension or diabetes by the NCEP-ATP III definition (HR, 1.78) but not by the AHA/NHLBI definition (HR, 1.28).
CONCLUSIONS: The metabolic syndrome was associated with increased risk of AF. The metabolic derangements of the syndrome may be important in the pathogenesis of AF.

Entities:  

Mesh:

Year:  2008        PMID: 18285562      PMCID: PMC2637133          DOI: 10.1161/CIRCULATIONAHA.107.744466

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  42 in total

1.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.

Authors:  Hanna-Maaria Lakka; David E Laaksonen; Timo A Lakka; Leo K Niskanen; Esko Kumpusalo; Jaakko Tuomilehto; Jukka T Salonen
Journal:  JAMA       Date:  2002-12-04       Impact factor: 56.272

2.  Obesity and type 2 diabetes in Japanese patients.

Authors:  Hirohito Sone; Hideki Ito; Yasuo Ohashi; Yasuo Akanuma; Nobuhiro Yamada
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

3.  Effect of C-reactive protein reduction on paroxysmal atrial fibrillation.

Authors:  John Dernellis; Maria Panaretou
Journal:  Am Heart J       Date:  2005-11       Impact factor: 4.749

4.  New criteria for 'obesity disease' in Japan.

Authors: 
Journal:  Circ J       Date:  2002-11       Impact factor: 2.993

5.  Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria.

Authors:  L Polontchouk; J A Haefliger; B Ebelt; T Schaefer; D Stuhlmann; U Mehlhorn; F Kuhn-Regnier; E R De Vivie; S Dhein
Journal:  J Am Coll Cardiol       Date:  2001-09       Impact factor: 24.094

6.  Obesity and the risk of new-onset atrial fibrillation.

Authors:  Thomas J Wang; Helen Parise; Daniel Levy; Ralph B D'Agostino; Philip A Wolf; Ramachandran S Vasan; Emelia J Benjamin
Journal:  JAMA       Date:  2004-11-24       Impact factor: 56.272

7.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

8.  Epidemiologic features of chronic atrial fibrillation: the Framingham study.

Authors:  W B Kannel; R D Abbott; D D Savage; P M McNamara
Journal:  N Engl J Med       Date:  1982-04-29       Impact factor: 91.245

9.  Gene expression profiling of oxidative stress on atrial fibrillation in humans.

Authors:  Young Hoon Kim; Do Sun Lim; Ji Hye Lee; Do-Sun Lim; Wan Joo Shim; Young Moo Ro; Gil Hong Park; Kevin G Becker; Yoon S Cho-Chung; Meyoung-Kon Kim
Journal:  Exp Mol Med       Date:  2003-10-31       Impact factor: 8.718

10.  Left atrial function and ventricular filling in hypertensive patients with paroxysmal atrial fibrillation.

Authors:  P Barbier; G Alioto; M D Guazzi
Journal:  J Am Coll Cardiol       Date:  1994-07       Impact factor: 24.094

View more
  124 in total

1.  Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study.

Authors:  Rachel R Huxley; Alvaro Alonso; Faye L Lopez; Kristian B Filion; Sunil K Agarwal; Laura R Loehr; Elsayed Z Soliman; James S Pankow; Elizabeth Selvin
Journal:  Heart       Date:  2011-09-19       Impact factor: 5.994

2.  Obesity and outcomes among patients with established atrial fibrillation.

Authors:  Afrooz Ardestani; Heather J Hoffman; Howard A Cooper
Journal:  Am J Cardiol       Date:  2010-08-01       Impact factor: 2.778

Review 3.  Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights.

Authors:  Jelena Kornej; Christin S Börschel; Emelia J Benjamin; Renate B Schnabel
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

4.  Anthropometric parameters and the incidence of atrial fibrillation in older people: the PRO.V.A study.

Authors:  Caterina Trevisan; Stefania Maggi; Chiara Curreri; Giovanni Nante; Marianna Noale; Marina De Rui; Egle Perissinotto; Leonardo Sartori; Sabina Zambon; Gaetano Crepaldi; Enzo Manzato; Giuseppe Sergi
Journal:  Clin Cardiol       Date:  2017-02-13       Impact factor: 2.882

Review 5.  Adaptation and maladaptation of the heart in obesity.

Authors:  Romain Harmancey; Christopher R Wilson; Heinrich Taegtmeyer
Journal:  Hypertension       Date:  2008-06-23       Impact factor: 10.190

Review 6.  Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation.

Authors:  Rachel R Huxley; Kristian B Filion; Suma Konety; Alvaro Alonso
Journal:  Am J Cardiol       Date:  2011-04-27       Impact factor: 2.778

7.  Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion.

Authors:  Babar Parvez; M Benjamin Shoemaker; Raafia Muhammad; Rachael Richardson; Lan Jiang; Marcia A Blair; Dan M Roden; Dawood Darbar
Journal:  Heart Rhythm       Date:  2013-02-19       Impact factor: 6.343

8.  Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop.

Authors:  Emelia J Benjamin; Peng-Sheng Chen; Diane E Bild; Alice M Mascette; Christine M Albert; Alvaro Alonso; Hugh Calkins; Stuart J Connolly; Anne B Curtis; Dawood Darbar; Patrick T Ellinor; Alan S Go; Nora F Goldschlager; Susan R Heckbert; José Jalife; Charles R Kerr; Daniel Levy; Donald M Lloyd-Jones; Barry M Massie; Stanley Nattel; Jeffrey E Olgin; Douglas L Packer; Sunny S Po; Teresa S M Tsang; David R Van Wagoner; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2009-02-03       Impact factor: 29.690

9.  A twin study of metabolic syndrome and autonomic tone.

Authors:  Anil K Gehi; Rachel Lampert; Emir Veledar; Forrester Lee; Jack Goldberg; Linda Jones; Nancy Murrah; Ali Ashraf; Viola Vaccarino
Journal:  J Cardiovasc Electrophysiol       Date:  2008-11-21

10.  Reversal rate of clustering of cardiovascular disease risk factors of metabolic syndrome in the general population: the niigata preventive medicine study.

Authors:  Shinsuke Okada; Akiko Suzuki; Hiroshi Watanabe; Toru Watanabe; Yoshifusa Aizawa
Journal:  J Obes       Date:  2010-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.